Description

Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan is a Drug-Linker Conjugates for ADC, which comprises a topoisomerase inhibitor and a linker for ligand unit connecting. Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan can be used to synthesis antibody-drug conjugate (ADC)[1].–20°C (Powder, sealed storage, away from moisture and light)-Applications-Cancer-programmed cell death-Formula-C57H77N7O18-Citation–References-[1]Philip Wilson Howard, et al. Compounds and conjugates thereof. Patent US20200306243A1.|[2]Schmidt, et al. Computer-based scoring method indicating a cancer patient’s response to an anti-B7H4 antibody-drug conjugate therapy using a convolutional neural network, WO2022053685, 2022.-CASNumber-2495742-34-0-MolecularWeight-1148.26-Compound Purity-98.95-SMILES-O=C1N2C(C(C(C2)=C3C4=C5CCC3)=NC4=CC=C5NC([C@H](C)NC([C@H](C(C)C)NC(CCOCCOCCOCCOCCOCCOCCOCCOCCNC(CCN6C(C=CC6=O)=O)=O)=O)=O)=O)=CC7=C1COC([C@]7(O)CC)=O-Research_Area-Cancer-Solubility-DMSO : 200 mg/mL (ultrasonic;warming;heat to 60°C)-Target-Drug-Linker Conjugates for ADC;Topoisomerase-Isoform-Camptothecins-Pathway-Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage-MCE Product type-ADC Related